Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab, Bendamustine and Rituximab in R/R Mantle Cell Lymphoma
NCT05868395Phase 2Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Jan 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin in mantle cell lymphoma (MCL), sponsored by Medical University of Vienna. Primary endpoint: Objective Response Rate at 36 months. Started Jan 2024; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05868395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868395.